Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Bilimsel Danışma Kurulu | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim  
2019, Cilt 33, Sayı 1, Sayfa(lar) 001-006   
CHANGES IN THE STAGES OF COPD PATIENTS AND EFFECT ON BRONCHODILATOR DRUG SELECTION ACCORDING TO GOLD 2017 REPORT
Filiz GÜLDAVAL, Ceyda ANAR, Melike YÜKSEL YAVUZ, Eylem YILDIRIM, İbrahim Onur ALICI, Melih BÜYÜKŞİRİN, Gülru POLAT, Gülistan KARADENİZ
İzmir Dr. Suat Seren Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim Araştırma Hastanesi, Göğüs Hastalıkları, İzmir, Türkiye
Keywords: COPD, GOLD quideline, treatment

Aim: We aimed to investigate the rate of changes in ABCD stages of COPD patients according to GOLD 2017 criteria and also to evaluate the effect of these changes on bronchodilator drug selection in treatment.Material and method: One hundred patients who were admitted to the outpatient clinic with a diagnosis of COPD between February 2017 and May 2017 were included in the study. Patients were classified using the classification criteria in GOLD 2011 and 2017. For this reason, the number of exacerbations, dyspnea score, FEV1% level were evaluated. Patients were grouped according to ABCD classification using these criteria. Medications used by patients in each group and currently using drugs were recorded.

Results: According to the GOLD that includes FEV1 value in classification, the rate of COPD patients in the A, B, C, and D stages was 8%, 10%, 14%, 68%, respectively. According to GOLD 2017 update (without FEV1 value), the stages of patients were 19%, 30%, 2% and 49%, respectively. A statistically significant difference was found between the two classifications (p: 0.002). In the selection of treatment according to classification that includes FEV1 value in staging system, there was a statistically significant difference for treatment selections between the two staging systems (p:0.000).

Conclusion: This study showed that the use of combined preparations (especially inhaled steroids) in treatment decreased due to the decrease of the number of patients in D and C groups according to GOLD 2017 update, and the monotherapy with LAMA or LABA increased.